IWQOL-Lite-CT

Weight affects things a bathroom scale cannot measure: whether you can tie your shoes comfortably, how you feel walking into a room, whether stairs are a decision. The Impact of Weight on Quality of Life questionnaire was built to capture that, and the Lite-CT version is the short form adapted specifically for clinical trials. Participants answer a fixed set of items; the answers roll up into a 0-to-100 score where higher is better, with physical-function and psychosocial parts reported separately.

Regulators care about this because losing weight is a means, not an end. A drug that moves the scale but leaves people no more able to live their lives has not delivered much. So obesity trials increasingly report a quality-of-life instrument alongside percent body weight, and the IWQOL-Lite-CT is the one that shows up most often in the semaglutide and tirzepatide programs.

It has a cousin worth knowing about. In heart failure trials such as STEP-HFpEF, the instrument used is the KCCQ-CSS rather than the IWQOL, because the question there is about breathlessness and physical limitation from heart failure specifically. Both are patient-reported; they simply point at different burdens.

The common confusion is reading a quality-of-life score as if it were a weight number. A 10-point gain on a 0-to-100 questionnaire is not “10% better” in any everyday sense, and the scores are not comparable across different instruments. A more useful way to read them: did the treated group improve more than the placebo group, and was the gap large enough that a typical person would notice it in daily life?

Worth asking your clinician: what improvement you personally are aiming for beyond a number — sleeping flat, walking a mile, getting off a blood-pressure pill — and how you will both check whether treatment delivered it. Our STEP 1 and SURMOUNT-1 pages summarize what the pivotal trials measured, and the weight-loss projection tool puts the scale numbers in personal terms.